Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cyclopharm Limited ( (AU:CYC) ) has issued an update.
Cyclopharm has entered into a clinical research collaboration with Macquarie University and Macquarie University Hospital to support the Endoscopic Segmental Sealant Ablation (ESSA) Study, which will test a novel minimally invasive bronchoscopic procedure for patients with severe COPD who are not eligible for existing valve-based lung volume reduction therapies. The trial, led by Professor Alvin Ing, will use Technegas® functional lung imaging combined with AI-based analysis from Thirona on V/Q SPECT-CT scans to identify poorly functioning lung segments, guide targeted treatment with polymer foam, and quantitatively measure segment-level treatment response in 34 patients over about 12 months, positioning Cyclopharm’s technology at the centre of a next‑generation, personalised approach to COPD care and potentially expanding its addressable market in interventional respiratory medicine.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited (ASX: CYC) is an Australian medical technology company focused on nuclear medicine and respiratory imaging, best known for its Technegas® system, which provides functional lung imaging to support the diagnosis and management of pulmonary and other advanced lung diseases. The company targets global respiratory and diagnostic markets, supplying technology that enables more precise assessment of lung function and supports interventional and personalised respiratory care.
Average Trading Volume: 62,816
Technical Sentiment Signal: Hold
Current Market Cap: A$97.8M
Learn more about CYC stock on TipRanks’ Stock Analysis page.